Vigabatrin in Drug-Resistant Epilepsy
A double-blind, placebo-controlled, crossover study of oral Vigabatrin (2-3 g/d) as add-on therapy for 31 patients with drug-resistant seizures is reported from the Neurological Clinic, Univ of Bologna School of Med, Italy.
Main Author: | |
---|---|
Format: | Article |
Language: | English |
Published: |
Pediatric Neurology Briefs Publishers
1987-10-01
|
Series: | Pediatric Neurology Briefs |
Subjects: | |
Online Access: | https://www.pediatricneurologybriefs.com/articles/3603 |